The market expects Biogen Inc. (BIIB) to deliver a year-over-year decline ... but a powerful factor that might influence its near-term stock price is how the actual results compare to these ...

Biogen (NASDAQ:BIIB – Free Report) had its price objective raised by Royal Bank of Canada from $221.00 to $225.00 in a research note issued to investors on Tuesday morning,Benzinga reports.

HSBC downgraded several major biotech names this week, citing macroeconomic sensitivities, tariff risks, and growing pressure from regulatory changes. Most notably, the bank downgraded Lilly to Reduce ...

Low-volatility stocks may offer stability, but that often comes at the cost of slower growth and the upside potential of more ...

In a report released yesterday, Salveen Richter from Goldman Sachs maintained a Buy rating on Biogen (BIIB – Research Report), with a price ...

Biogen’s lack of insider buying and reduced R&D spending raise concerns, but its future growth prospects remain. Find out why ...

In a report released yesterday, Brian Abrahams from RBC Capital maintained a Buy rating on Biogen (BIIB – Research Report), with a price target ...

Biogen (BIIB) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

The Medicines and Healthcare products Regulatory Agency (MHRA) has approved Skyclarys (omaveloxolone), the first treatment ...

As April gives way to May, the market braces for a blockbuster week packed with earnings from some of the biggest names ...